Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 29, 2018
TickeronGET DAILY SIGNALS
INVESTOR'S: This Highly Rated Pharma Giant Is More Than Just A Diabetes Player

INVESTOR'S: This Highly Rated Pharma Giant Is More Than Just A Diabetes Player

Investors may know Eli Lilly (LLY) as a venerable member of the Big Pharma club whose bread and butter now comes from diabetes treatments. But analysts say Lilly stock is due for a boost from the drug giant's burgeoning migraine prevention and immunology medicines.

READ MORE...

Related Ticker: LLY

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


LLY in upward trend: price rose above 50-day moving average on October 14, 2026

LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 58 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.

The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 54%.

Following a +5.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 260 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 217 of 298 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (35.624) is slightly higher than the industry average of (-1.421). P/E Ratio (45.360) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 7%. MIRA experienced the highest price growth at 20%, while SCLX experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -5% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 31
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 58
Seasonality Score: 14 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
Lilly Corporate Center
Phone
+1 317 276-2000
Employees
50000
Web
https://www.lilly.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
Nebius Group N.V. is expected to report third-quarter 2026 results in early November, following a second quarter in which revenue surged 454% year over year. Wall Street consensus tracked by Benzinga points to roughly $937 million in Q3 2026 revenue, up from $146.1 million in the year-ago quarter.
INVESTOR'S: This Highly Rated Pharma Giant Is More Than Just A Diabetes Player